.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG04_Belimumab.Belimumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG04_Belimumab.Belimumab| name: | Belimumab |
| ATC code: | L04AG04 | route: | intravenous |
| n-compartments | 2 |
Belimumab is a fully human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS or BAFF) and is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE) in adults and pediatric patients. It is administered as an adjunct to standard therapy and reduces disease activity by limiting the survival and differentiation of B cells.
Population pharmacokinetics in adult patients with SLE following intravenous administration. Mixed sex, adult patients, typical body weight 76 kg.
Struemper, H, et al., & Cai, W (2013). Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. Journal of clinical pharmacology 53(7) 711–720. DOI:10.1002/jcph.104 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23681782
Dimelow, R, et al., & Struemper, H (2021). Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. Clinical pharmacology in drug development 10(6) 622–633. DOI:10.1002/cpdd.889 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33245847
Zhou, X, et al., & Ma, P (2021). Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs in R&D 21(4) 407–417. DOI:10.1007/s40268-021-00363-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34628605